Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER
      

Genmab: Epcoritamab video


84649 Helge Larsen/PI-redaktør 12/6 2020 08:13
Oversigt

Learn more about the proposed mechanism of action of epcoritamab (DuoBody-CD3xCD20).

Epcoritamab is a proprietary bispecific antibody created using Genmab's DuoBody® technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B-cell malignancies. Please note, Epcoritamab is an investigational compound and its safety and efficacy has not been established. For more information, please contact medinfo@genmab.com




TRÅDOVERSIGT